Aptevo Therapeutics Inc. Expected to Earn FY2028 Earnings of $2.76 Per Share (NASDAQ:APVO)

Aptevo Therapeutics Inc. (NASDAQ:APVO) – Equities researchers at Roth Capital issued their FY2028 earnings per share (EPS) estimates for Aptevo Therapeutics in a research report issued on Friday, April 19th. Roth Capital analyst J. Aschoff anticipates that the biotechnology company will post earnings per share of $2.76 for the year. The consensus estimate for Aptevo Therapeutics’ current full-year earnings is ($57.83) per share.

Separately, StockNews.com initiated coverage on Aptevo Therapeutics in a research report on Thursday, April 18th. They set a “sell” rating for the company.

Aptevo Therapeutics Trading Up 3.7 %

Aptevo Therapeutics stock opened at $0.74 on Monday. The stock has a 50-day moving average price of $4.43 and a 200 day moving average price of $7.46. Aptevo Therapeutics has a 52 week low of $0.67 and a 52 week high of $91.96.

Institutional Trading of Aptevo Therapeutics

A hedge fund recently bought a new stake in Aptevo Therapeutics stock. Armistice Capital LLC purchased a new position in Aptevo Therapeutics Inc. (NASDAQ:APVO) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 1,235,000 shares of the biotechnology company’s stock, valued at approximately $408,000. Armistice Capital LLC owned about 10.72% of Aptevo Therapeutics at the end of the most recent quarter. 8.06% of the stock is owned by hedge funds and other institutional investors.

About Aptevo Therapeutics

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.